Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -216.84% is 95% above its 5-year average of -4092.56%, near the high end of its 5-year range (-24236.64%–-16.72%).
83.45% below its 12-month average of -118.20%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -82.21%.
RETURN ON ASSETS (ROA)
-216.84%
RETURN ON ASSETS (ROA) AVG TTM
-118.20%
RETURN ON ASSETS (ROA) AVG 3Y
-6127.40%
RETURN ON ASSETS (ROA) AVG 5Y
-4092.56%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-83.45%
CURRENT VS 3Y AVG
+96.46%
CURRENT VS 5Y AVG
+94.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.75%
median of 729 covered companies
CURRENT VS SECTOR MEDIAN
-605.17%
vs the sector median at left
Lantern Pharma Inc.
Market Cap
$13.01M
Return on Assets (ROA)
-216.84%
TTM Avg
-118.20%
3Y Avg
-6127.40%
5Y Avg
-4092.56%
Market Cap
$12.86M
Return on Assets (ROA)
-60.93%
TTM Avg
-160.25%
3Y Avg
-205.49%
5Y Avg
-152.09%
Market Cap
$12.60M
Return on Assets (ROA)
-47.98%
TTM Avg
-31.15%
3Y Avg
-42.27%
5Y Avg
-34.21%
Market Cap
$12.56M
Return on Assets (ROA)
-49.12%
TTM Avg
-29.80%
3Y Avg
-67.98%
5Y Avg
-117.36%
Market Cap
$12.98M
Return on Assets (ROA)
-143.44%
TTM Avg
-68.17%
3Y Avg
-65.00%
5Y Avg
-57.74%
Market Cap
$12.37M
Return on Assets (ROA)
-13.01%
TTM Avg
-15.22%
3Y Avg
-24.53%
5Y Avg
-20.43%
Market Cap
$13.48M
Return on Assets (ROA)
-27.12%
TTM Avg
-32.94%
3Y Avg
-35.27%
5Y Avg
-29.16%
Market Cap
$11.81M
Return on Assets (ROA)
-198.70%
TTM Avg
-189.50%
3Y Avg
-187.22%
5Y Avg
-200.18%
Market Cap
$13.72M
Return on Assets (ROA)
-123.23%
TTM Avg
-153.35%
3Y Avg
-205.77%
5Y Avg
-166.29%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | $13.01M | -216.84% | -118.20% | -6127.40% | -4092.56% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.86M | -60.93% | -160.25% | -205.49% | -152.09% |
| Cytosorbents Corporation (CTSO)vs › | $12.60M | -47.98% | -31.15% | -42.27% | -34.21% |
| Dare Bioscience, Inc. (DARE)vs › | $12.56M | -49.12% | -29.80% | -67.98% | -117.36% |
| Passage Bio, Inc. (PASG)vs › | $12.98M | -143.44% | -68.17% | -65.00% | -57.74% |
| IRIDEX Corporation (IRIX)vs › | $12.37M | -13.01% | -15.22% | -24.53% | -20.43% |
| Optimi Health Corp. (OPTH)vs › | $13.48M | -27.12% | -32.94% | -35.27% | -29.16% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.81M | -198.70% | -189.50% | -187.22% | -200.18% |
| Vyome Holdings, Inc. (HIND)vs › | $13.72M | -123.23% | -153.35% | -205.77% | -166.29% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $11.73M | -77.94% | -178.68% | -1009.31% | -2782.57% |
ROA
-216.8%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -155.13% |
| 2024-12-31 | -81.27% |
| 2023-12-31 | -36.57% |
| 2022-12-31 | -24236.64% |
| 2021-12-31 | -16.72% |
| 2020-12-31 | -29.02% |
| 2019-12-31 | -169.50% |
| 2018-12-31 | -383.79% |
